Arax Advisory Partners’s Ionis Pharmaceuticals IONS Stock Holding History

Arax Advisory Partners’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$79.6K	Buy	+1,004	New	+$75.6K	﹤0.01%	2896
2026 Q1	–	Sell	-774	Closed	-$61.2K	–	4067
2025 Q4	$61.2K	Buy	+774	New	+$58.3K	﹤0.01%	1512
2025 Q3	–	Sell	-156	Closed	-$6.17K	–	3950
2025 Q2	$6.17K	Buy	156 +52	+50%	+$1.7K	﹤0.01%	2165
2025 Q1	$3.14K	Hold	104	–	–	﹤0.01%	1942
2024 Q4	$3.64K	Hold	104	–	–	﹤0.01%	1847
2024 Q3	$4.17K	Hold	104	–	–	﹤0.01%	1792
2024 Q2	$4.96K	Buy	104 +79	+316%	+$3.24K	﹤0.01%	1600
2024 Q1	$1.08K	Sell	25 -59	-70%	-$2.81K	﹤0.01%	1141
2023 Q4	$4.25K	Buy	84 +44	+110%	+$2.11K	﹤0.01%	914
2023 Q3	$1.81K	Sell	40 -58	-59%	-$2.39K	﹤0.01%	1030
2023 Q2	$4.02K	Buy	98 +9	+10%	+$346	﹤0.01%	906
2023 Q1	$3.18K	Buy	89 +74	+493%	+$2.78K	﹤0.01%	938
2022 Q4	$567	Sell	15 -22	-59%	-$925	﹤0.01%	1166
2022 Q3	$2K	Buy	+37	New	+$1.56K	﹤0.01%	961
2022 Q1	–	Sell	-38	Closed	-$1K	–	1176
2021 Q4	$1K	Buy	+38	New	+$1.2K	﹤0.01%	1032
2020 Q1	–	Sell	-30	Closed	-$2K	–	699
2019 Q4	$2K	Hold	30	–	–	﹤0.01%	552
2019 Q3	$2K	Hold	30	–	–	﹤0.01%	553
2019 Q2	$2K	Buy	+30	New	+$2.12K	﹤0.01%	553
2018 Q4	$2K	Hold	30	–	–	﹤0.01%	528
2018 Q3	$2K	Buy	+30	New	+$1.41K	﹤0.01%	572

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Arax Advisory Partners's IONS Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Ionis Pharmaceuticals (IONS) in Q2 2026: 1,004 shares worth $79.6K. The stake represents ﹤0.01% of the portfolio and ranks #2896 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in IONS as recently as Q4 2025.

Arax Advisory Partners first reported a position in IONS in Q3 2018 and has held it in 20 quarters since. 513 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

Arax Advisory Partners held 1,004 shares of Ionis Pharmaceuticals worth $79.6K as of Q2 2026.
Ionis Pharmaceuticals was a new Arax Advisory Partners position in Q2 2026.
Ionis Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2896 holding.
Arax Advisory Partners first reported a position in Ionis Pharmaceuticals in Q3 2018 and has held it in 20 quarters since.
513 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.